Post-approval studies (Phase 4)Study completedNCT00670930
What this trial is testing
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
Who this might be right for
Allergic Asthma
Novartis Pharmaceuticals 36